Survival in Cervical Cancer and Its Predictors at Ocean Road Cancer Institute From January to December 2012

PURPOSEIn Tanzania, cancer of cervix is the most commonly diagnosed cancer and is the leading cause of cancer-related deaths. There are very little data about survival of patients with cervical cancer after treatment in Tanzania. The aims of this study were to determine 5-year overall survival (OS)...

Full description

Bibliographic Details
Main Authors: Salama Iddy Khamis, Alita S. Mrema, Johnson Katanga, Emmanuel L. Lugina
Format: Article
Language:English
Published: American Society of Clinical Oncology 2021-12-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO.20.00616
Description
Summary:PURPOSEIn Tanzania, cancer of cervix is the most commonly diagnosed cancer and is the leading cause of cancer-related deaths. There are very little data about survival of patients with cervical cancer after treatment in Tanzania. The aims of this study were to determine 5-year overall survival (OS) rate and its predictors among patients with cervical cancer treated at Ocean Road Cancer Institute (ORCI) from January to December 2012.MATERIALS AND METHODSThis was retrospective study done at ORCI by reviewing medical charts of 202 patients with cervical cancer treated at ORCI from January to December 2012. A structured questionnaire was used to extract information about characteristics of the respondents. Survival curves were estimated by using Kaplan-Meir analysis and were compared by using log-rank test.RESULTSThe 5-year OS rate was 26%. The mean and median survival times were 33.9 and 19 months, respectively. Factors that were positively associated with 5-year OS rate include the hemoglobin level more than 9 g/dL at presentation, early International Federation of Gynecology and Obstetrics stage at presentation, high dose of radiotherapy, and use of concurrent chemoradiotherapy. Histology type and HIV status were not associated with survival.CONCLUSIONThe 5-year overall survival rate was 26%. Predictors of OS were hemoglobin level, stage at presentation, radiotherapy dose, and the use of concurrent chemoradiotherapy.
ISSN:2687-8941